Geoclock: customisable oral chronotherapy

Geoclock™ is a validated oral drug delivery technology that can be used to release the drug from the tablet after a pre-determined lag-time that is independent of food or pH. Geoclock™ can additionally be used for multiple pulse delivery of one or more drugs with pre-determined time intervals between the pulses, or to target colonic release of drugs. Where more than one drug is included, the delivery profile can be different for each active pharmaceutical ingredient. Geoclock™ is easily manufactured using conventional production equipment, minimising the need for capital investment.

Geoclock allows timed release of a drug without a food or pH effect


How Geoclock™ works

Geoclock™ is a dry-coated tablet with an active drug core inside an outer tablet layer comprising a mixture of hydrophobic wax and brittle material. This configuration generates a pH-independent lag-time prior to the release of the active drug. After the pre-defined and configurable lag-time the inner tablet releases the active drug either as a burst or with a controlled release pattern. The controlled release characteristics of the inner core can be modified to achieve the desired profile.

Benefits of Geoclock™

Geoclock™ can be used to create chronotherapy-focused drug delivery that is independent of the location in the GI tract, pH or food. Examples of the application of Geoclock™ include:

  • A burst release after a long lag-time or a slow release rate after a short lag-time
  • Drug delivery specifically at the colonic level, which is valuable for drugs targeted for colonic absorption
  • Multiple pulse release e.g. to mimic multiple daily dosing of conventional formulations

Geoclock™ is a validated technology that has been incorporated into products that are approved and on the market in the US and Europe. Tablets can be manufactured using standard tableting equipment, minimizing the need for additional capital investment.

Products and projects incorporating Geoclock™

Geoclock™ has been incorporated into products that are approved and on the market in the US and Europe, and to products in development:

LODOTRA® / RAYOS®, SKP-1041, SKP-1052

> Download a leaflet [PDF 1.0 MB]

Contact us to find out how we can help with your oral drug delivery project.

Copyright 2014, Skyepharma. All Rights Reserved. Skyepharma PLC is a public limited company registered in England and Wales, registration number 0107582.
Registered office: 46-48 Grosvenor Gardens, London SW1W 0EB, United Kingdom

Contact addresses

Skyepharma PLC
46-48 Grosvenor Gardens
London
SW1W 0EB
UK

Tel: +44 207 881 0524

Fax: +44 207 881 1199

E-mail us

Skyepharma AG
Eptingerstrasse 61
4132 Muttenz
Switzerland

Tel: +41 61 467 5555

Fax: +41 61 467 5500

E-mail us

This website works best using cookies.